Latest News & Features
Big Pharma
By facilitating public access to the work being done, universities face the challenge of maintaining a balance between being transparent and commercialising IP. LSIPR spoke to the head of the University of Manchester IP about walking the fine line. 28 November 2014
article
The lights of Oxford and Cambridge University might shine brightest, but there is more than a flicker of success at other academic institutions in the UK. One of those, the University of Manchester, boasts 25 Nobel Prize winners and has housed academic masterminds such as Alan Turing. 28 November 2014
Asia
India has been urged once again to strengthen its IP laws, particularly those covering drugs, following a visit from the US Trade Representative. 27 November 2014
Americas
The Supreme Court of Canada was expected to bring the Canadian law on utility more into line with other jurisdictions, but those hopes have now received a setback, as Gunars Gaikis of Smart & Biggar/Fetherstonhaugh reports. 27 November 2014
Americas
Google’s new contact lens sensor is just one of the latest eye-based devices that has vast potential in the field of medicine. LSIPR reports. 27 November 2014
Big Pharma
There still are some cultural, legal and procedural barriers that must be overcome before the potential of Brazil’s life sciences sector can be realised, as Gabriel Di Blasi and Mellina Mamede of Di Blasi, Parente & Associados explain. 27 November 2014
Big Pharma
The current regulations in Mexico provide a legal framework for protecting genetic resources, but the framework for investing in new biotechnology is still not clear, as Karla Roxana Aispuro Castro and Mariana González Vargas of Becerril, Coca & Becerril report. 27 November 2014
article
The Indian Patent Office has issued guidelines aimed at bringing together the intentions of the Patents Act and the Biological Diversity Act, but this has posed serious challenges in obtaining patent protection, say Ranjna Mehta-Dutt and Neha Srivastava of Remfry & Sagar. 27 November 2014
Americas
The US Supreme Court has now heard arguments in the appeal of Teva v Sandoz from the US Court of Appeals for the Federal Circuit. This could fundamentally change how patent decisions are reviewed by the Federal Circuit and the deference given to district court rulings, says Felicia Boyd of Barnes & Thornburg. 27 November 2014
Big Pharma
The UK Intellectual Property Enterprise Court offers a quick and cheap way to resolve IP disputes, but very few have involved life sciences inventions. Mark Didmon and Simon Curtis of Potter Clarkson ask whether IPEC is an appropriate forum for handling these types of patent disputes. 27 November 2014